2668results about "Glycosylases" patented technology

The invention provides a Kitasatospora xanthophycea JY01 strain and application thereof, the strain is separated from intestinal tracts of spring silkworms, has good disease-resistant and growth-promoting effects, and is specifically expressed in that cellulase, beta-1, 3-glucanase, siderophore and auxin IAA can be secreted; pot experiments show that the biocontrol efficiency of the microbial inoculum to wheat stalk rot is 57.90%, the biocontrol efficiency of the microbial inoculum to corn stalk rot is 46.41%, and the plant height and fresh weight are both significantly increased. The microbial agent is expected to be applied to preparation of biological bacterial fertilizer for effectively preventing and controlling soil-borne fungal diseases.

Methods for stimulating plant growth and / or promoting plant health using free enzymes or recombinant microorganisms that overexpress enzymes are provided. Plant seeds coated with free enzymes or recombinant microorganisms that overexpress enzymes are also provided. Compositions comprising a fertilizer and an enzyme or a recombinant microorganism that overexpresses an enzyme are provided. Modified enzymes having ACC deaminase activity, recombinant microorganisms expressing the modified enzymes, plant seeds treated with the modified enzymes or recombinant microorganisms, and methods for stimulating plant growth and / or promoting plant health using the modified enzymes or recombinant microorganisms are also provided.

The present invention is related to the field of protein engineering technology which increases the enzymatic activity and thermal stability of human hyaluronidase which is an enzyme that hydrolyzes hyaluronic acid; and more particularly to hyaluronidase PH20 variants or fragments thereof, which comprise one or more amino acid residue substitutions in the region corresponding to the alpha-helix region and its linker region in the amino acid sequence of wild-type PH20 of SEQ ID NO: 1 and in which one or more amino acid residues at the N-terminus and / or the C-terminus are selectively cleaved additionally.Specifically, the present invention relates to PH20 variants or fragments thereof, which comprise one or more amino acid residue substitutions selected from the group consisting of T341A, T341C, T341G, S343E, M345T, K349E, L353A, L354I, N356E and I361T in wild-type PH20 having the amino acid sequence of SEQ ID NO: 1, and additionally comprise the substitution of amino acids located in the alpha-helix 8 region and / or a linker region between alpha-helix 7 and alpha-helix 8 in the amino acid sequence of wild-type PH20, and in which one or more amino acids located at the N-terminal and C-terminal regions are deleted.

The present disclosure provides proteins useful for preventing, treating, suppressing and / or eliminating infestations and infections of plants by various phytopathogenic pests, as well as formulations comprising such proteins, polynucleotides encoding such proteins, organisms expressing such proteins, and methods of using such proteins, formulations, polynucleotides and organisms in agriculture and other fields of endeavor.

The invention discloses an aspergillus niger recombinant bacterium AnCT-XynB-K-agdA and application thereof, and belongs to the technical field of microbiology and bioengineering. According to the invention, Aspergillus niger AnCat is taken as an expression host, firstly, an acid protease regulatory factor prtT is knocked out to obtain a defective strain, and then different chaperonins are subjected to fusion expression by optimizing integration sites of a laccase lcc9 expression cassette, so that the high-expression laccase chaperonin is obtained. According to the method, an expression vector pC3-5 'agdA-PcitA-XynB-L-lcc9-hph-3' agdA is constructed, a recombinant bacterium AnCT-XynB-K-agdA is further obtained, the enzyme activity of the extracellular laccase subjected to shake flask fermentation reaches 1821.2 U / L, and finally, the recombinant efficient expression of the laccase Lcc9 in aspergillus niger is realized.

The invention discloses a multifunctional cellulolytic enzyme and application thereof in degradation of agricultural by-products, and belongs to the technical field of biology. The multifunctional cellulolytic enzyme is named RuCelI, and the amino acid sequence of the multifunctional cellulolytic enzyme is as shown in SEQ ID NO. 1. Based on a rumen microbial metagenome resource mining technology, a novel multifunctional cellulose decomposition enzyme RuCelI is developed, and the enzyme has double activities of endo-cellulase and xylanase, can be used for degrading agricultural by-products, reducing the treatment cost and improving the degradation efficiency, and is beneficial to improving the utilization rate and the economic benefit of the agricultural by-products.

The invention discloses a molecular modification design method for improving the catalytic activity and the thermal stability of citrobacter vinegaticus-derived hyaluronidase and expression application of the citrobacter vinegaticus-derived hyaluronidase. The interaction of citrobacter vinegaticus hyaluronidase active pocket amino acid residues and hyaluronate tetrasaccharide molecules is visually explored through Pymol, conservative analysis of pocket amino acid evolution is carried out through Consurf, and rational design is carried out through policies of FoldX for calculating enzyme-substrate binding free energy, so that the hyaluronidase catalytic activity is improved. A mutant with significantly improved enzyme activity is obtained through screening, and the thermal stability of the enzyme is further improved through PROSS design and an analysis strategy of mutation site amino acid evolution conservative property and position. According to the invention, the sequence, structure and function of hyaluronidase are deeply studied, and hyaluronidase is mutated from two aspects of stabilizing a catalytic structure and promoting a catalytic reaction, so that a high-activity enzyme with higher application value in industrial production is obtained.

The invention discloses an endoglucanase truncated mutant and an application of the endoglucanase truncated mutant. According to the invention, based on endoglucanase BsEGL from bacillus subtilis DLG, a truncated mutant is constructed by deleting a carbohydrate binding domain (CBM) of the endoglucanase BsEGL, and the truncated mutant is named as BsEGL [delta] CBM. Compared with BsEGL, the truncated mutant BsEGL delta CBM has the advantages that the thermal stability, the pH stability, the organic solvent tolerance and the like are remarkably improved, and the activity of degrading phosphoric acid expanded cellulose and corncob xylan is obtained. In addition, the enzymatic activity of the truncated mutant BsEGL delta CBM is remarkably improved by 6.41%, and the catalytic efficiency is remarkably improved. Due to the characteristics, the mutant can be suitable for industrial processes such as feed processing, papermaking, biological energy sources, spinning and food brewing, and is particularly suitable for enzyme catalytic reaction under extreme environments such as high temperature and low pH. The invention provides an enzyme preparation tool with excellent performance for efficient degradation of cellulose biomass, and has important application value.

The invention provides an H1N1 broad-spectrum mRNA (messenger ribonucleic acid) vaccine taking HA (hemagglutinin) and NA (neuraminidase) protein tandem as a target and a preparation method of the H1N1 broad-spectrum mRNA vaccine, and relates to the technical field of vaccine preparation, the amino acid sequence of the mRNA vaccine is shown as SEQ ID NO.1, and the nucleotide sequence of the mRNA vaccine is shown as SEQ ID NO.2, namely, the mRNA vaccine is obtained by connecting GGGSGGSGGGSGGGGS with conserved amino acid sequences of hemagglutinin HA and neuraminidase NA. The defects in the prior art are overcome, and the broad spectrum and the protection effect of the vaccine are improved, so that the vaccine can better cope with the immune escape of the latest variant in the future.

The invention belongs to the technical field of biology, in particular to the technical field of agricultural biology. More specifically, the present invention relates to methods for modulating carbon assimilate distribution to increase plant yield by gene editing (e.g., guided editing) precise introduction of environmentally responsive elements.

The invention relates to the technical field of synthetic biology, metabolic engineering and cell culture. The present invention provides a cell for the production of a negatively charged, preferably sialylated, oligosaccharide wherein the cell is genetically engineered to have or express, preferably overexpress, a hydrolytic UDP-N-acetyl-D-glucosamine-2-epimerase. The invention further provides the use of said cells in culture or incubation. Also described are methods of producing negatively charged, preferably sialylated oligosaccharides using the cells, and purification of the negatively charged, preferably sialylated oligosaccharides.

The invention belongs to the technical field of bioengineering technologies, and particularly relates to heparanase sulfate as well as a preparation method and application thereof. The amino acid sequence of the heparanase sulfate (HPSE) is as shown in SEQ ID NO. 2. The HS carbohydrate chain substrate capable of being specifically degraded by the heparan sulfate enzyme (WJS HPSE) provided by the invention is white jade snail polysaccharide (WJS PS) containing an IdoA2S-GlcNAc disaccharide repeating unit, heparin or HS. In addition, the heparan sulfate enzyme (WJS HPSE) provided by the invention is high in thermal stability and has optimal enzyme activity at the temperature of 57-67 DEG C and the pH value of 4.0, and the stability and reutilization efficiency of the heparan sulfate enzyme in a catalytic process are remarkably improved, so that the application value of the HPSE is improved.

Methods for stimulating plant growth and / or promoting plant health using free enzymes or recombinant microorganisms that overexpress enzymes are provided. Plant seeds coated with free enzymes or recombinant microorganisms that overexpress enzymes are also provided. Compositions comprising a fertilizer and an enzyme or a recombinant microorganism that overexpresses an enzyme are provided. Modified enzymes having ACC deaminase activity, recombinant microorganisms expressing the modified enzymes, plant seeds treated with the modified enzymes or recombinant microorganisms, and methods for stimulating plant growth and / or promoting plant health using the modified enzymes or recombinant microorganisms are also provided.

The invention discloses application of acinetobacter baumannii bacteriophage depolymerases in preparation of bacteriostatic agents, and relates to the technical field of biology. The depolymerases disclosed by the invention can inhibit the growth of a plurality of acinetobacter baumannii, have a bacteriostatic effect on the acinetobacter baumannii, and lay a foundation for developing effective infection control strategies and treatment methods to resist infection of the multi-drug-resistant acinetobacter baumannii.

The invention discloses bacillus subtilis engineering bacteria capable of efficiently producing pullulanase and application of the bacillus subtilis engineering bacteria in trehalose enzyme method production, and belongs to the technical field of genetic engineering. The invention discloses a bacillus subtilis engineering bacterium capable of efficiently producing pullulanase. The bacillus subtilis engineering bacterium comprises a pullulanase gene of which the nucleotide sequence is as shown in SEQ ID NO.7. According to the invention, the bacillus subtilis strain is used as an expression host, and the bacillus subtilis is modified through an engineering technical means, so that the pullulanase is highly expressed, and the fermentation cost of pullulanase liquid in the production process of trehalose is reduced.

The invention provides a uracil production strain and a construction method and application thereof.According to the strain, on an E.coli UR14 genome by means of a CRIPSR / Cas9 gene editing technology, firstly, psuG genes, preTA genes, rutA genes and upp genes are knocked out, so that decomposition of uracil is blocked; then, a uridine phosphorylase gene udp and a pyrimidine-5 '-nucleotide nucleotidase gene ppnN are subjected to overexpression, and synthesis and accumulation of uracil are synergistically enhanced; and finally, overexpression of the ribose phosphate mutase gene pgm further enhances the conversion of a by-product ribose phosphate 1-precursor 5-ribose phosphate 1-pyrophosphate and improves the carbon utilization rate, and the obtained strain has good genetic stability and high fermentation yield, can stably produce uracil, and has wide application prospects.

Described herein are antibodies, or antigen binding fragments thereof, that bind OX40L and IL- 13 in combination and methods of use thereof. In certain aspects, described herein are methods of inhibiting OX40L and IL- 13 biological activity. In certain aspects, described herein are pharmaceutical compositions comprising the anti-OX40L and anti-IL-13 antibodies, or antigen binding fragments thereof. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder (e.g., associated with elevated levels of OX40L and / or IL- 13). Also described herein are compositions and combinations comprising an antibody or an antigen binding region that binds OX40L, an antibody or antigen binding region that binds IL- 13, and a hyaluronidase or variant thereof, as well as related methods of treating an inflammatory disorder or disease in a human patient by administering such compositions and combinations.

Aspects of the disclosure relate to complexes comprising an anti-TfR1 antibody covalently linked (e.g., via a linker such as a peptide linker) to a lysosomal enzyme (e.g., an acid alpha glucosidase enzyme), and methods of making and using the fusion complexes to treat a lysosomal storage disease (e.g., Pompe disease).

The invention provides Aspergillus tubingensis HNZY02, a method for producing enzymes by the Aspergillus tubingensis HNZY02 and application of the Aspergillus tubingensis HNZY02, and belongs to the technical field of microorganisms, the Aspergillus tubingensis HNZY02 is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.42148. The aspergillus tubingensis HNZY02 shows excellent cellulase and xylanase synthesis capability, can synergistically and efficiently degrade main structural components such as cellulose, hemicellulose and lignin in tobacco stems, and improves the safety and application value of cigarettes while breaking the compact structure and increasing the reducing sugar content.

The invention discloses lysozyme, antibacterial peptide derived from the lysozyme and application of the lysozyme in preparation of antibacterial drugs. According to the invention, 1, 640 protein sequences recorded in a ruminant rumen caterpillars genome database are systematically predicted based on a lysozyme prediction model, and finally, the lysozyme with the amino acid sequence as shown in SEQ ID No.1 is relatively strong in antibacterial activity and stable in antibacterial activity, and is slightly influenced by environmental factors. According to the invention, an antibacterial peptide region of the lysozyme is analyzed and determined, three peptide fragments with clear antibacterial activity are identified, and the amino acid sequences of the peptide fragments are respectively shown as SEQ ID No.2, SEQ ID No.3 or SEQ ID No.4. The antibacterial peptide provided by the invention has relatively strong membrane destroying ability and broad-spectrum antibacterial activity, and compared with integral protein, the antibacterial peptide is simpler in structure and more flexible in synthesis and modification, and is easier to break through a bacterial drug-resistant mechanism.

Provided herein are methods of inserting a nucleic acid encoding a polypeptide of interest into a target genomic locus in a cell or a population of cells in a subject, methods of expressing a polypeptide of interest from a target genomic locus in a cell or a population of cells in a subject, methods of treating an enzyme deficiency in a subject in need thereof, and methods of preventing or reducing the onset of a sign or symptom of an enzyme deficiency in a subject in need thereof. The methods use CD40 inhibitors (e.g., CD40 antigen-binding molecules) to mitigate immune response and facilitate redosing of nucleic acid constructs encoding a polypeptide of interest and nuclease agents targeting a target genomic locus to achieve, for example, a step-wise increase in expression of a polypeptide of interest in a subject following insertion of the nucleic acid construct without overshooting.

The invention provides a high-activity chitinase mutant and application thereof in degradation of crustacean waste, and belongs to the technical field of enzyme engineering and agricultural waste conversion. According to the invention, chitinase PbChi from Paenibacillus barengltzii is subjected to molecular modification, and a plurality of chitinase mutants with high activity are successfully constructed by increasing the flexibility of a connexin, changing steric hindrance at a substrate catalytic crack inlet and changing catalytic residues in a beta sheet layer in a catalytic structural domain through calculation design and experimental verification; the chitinase mutant can effectively degrade shrimp shell meal, so that carapace waste is effectively utilized, and the chitinase mutant has a wide application prospect in the biological feed industry.

The purpose of the present invention is to provide a method for producing a methyl compound. Provided is a method for producing a methyl compound using formic acid.

The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

The present invention relates to treatment of IgE-mediated disease with antibodies that specifically bind CD38.

The invention provides a saccharomyces cerevisiae engineering strain HYB05 capable of releasing astaxanthin in a controllable self-splitting manner. The saccharomyces cerevisiae engineering strain HYB05 is constructed by taking a basic strain for producing astaxanthin as a starting strain, introducing a coding sequence comprising cell wall lyase Lyc, a coding sequence of a signal peptide mutant F8A and a recombinant nucleic acid construct for expressing a regulatory element, and knocking out an SSD1 gene to relieve a translation inhibition effect. The cell wall lyase Lyc is found and disclosed by the inventor for the first time, and the amino acid sequence is shown as SEQ ID NO: 6; the amino acid sequence of the signal peptide mutant F8A is as shown in SEQ ID NO: 8. According to the engineering strain HYB05, by introducing the recombinant nucleic acid construct, the activation of the catalytic activity of cell wall lyase under specific conditions is realized, so that the cell wall of the saccharomyces cerevisiae is broken, and the astaxanthin synthesized by the saccharomyces cerevisiae is released. Compared with the prior art, the astaxanthin is produced through fermentation of the strain, the extraction steps are simplified, extraction of the astaxanthin in the yeast is achieved to the maximum extent, the yield of the astaxanthin is remarkably increased, and the technical effect is remarkable.

The invention relates to the technical field of gene engineering, and particularly discloses streptococcus agalactiae WC1535 delta cps delta hylB as well as a construction method and application thereof. The streptococcus agalactiae WC1535 [delta] cps [delta] hylB is preserved in Guangdong Microbial Culture Collection Center on February 28, 2025, the preservation number is GDMCC NO.65955, and the address of the preservation unit is the 5th building, No. 59 building, No. 100 Courtyard, Xianlie Middle Road, Guangzhou. Compared with a traditional single-fragment deletion method, the toxicity of the deletion strain is not prone to being enhanced, and compared with a traditional injection immune vaccine, the gene deletion strain is used for preparing the tilapia oral live vaccine, the immune operation is simpler, and more labor cost is saved.

The invention belongs to the technical field of genetic engineering, and particularly relates to a method for regulating and controlling production of human milk oligosaccharide through membrane protein. The method is realized by inactivating a membrane protein YgfX coding gene on a production strain. According to the human milk oligosaccharide production strain obtained in the mode that the membrane protein YgfX is inactivated after the coding gene of the membrane protein YgfX is knocked out or deleted from a 192nd guanine base through a gene editing technology, the human milk oligosaccharide production capacity of the human milk oligosaccharide production strain is obviously improved compared with that before gene editing, the yields of LNTII, LNnT, LNT, 3 '-SL and 6'-SL are improved by about 40%, 125%, 46%, 32% and 47% respectively, the effect is remarkable, and the human milk oligosaccharide production strain has a good application prospect. And a new method and thought are provided for widening the production way of the human milk oligosaccharide.